Specialist-Oriented Products Now Account for a Growing Share of Blockbuster Drugs.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c46412) has announced the addition of the Decision Resources report "Blockbusters are Alive and Well: Why their Numbers Continue to Rise" to their offering. Despite changes in the pharmaceutical industry and a marked slowdown in the number of new drugs launched, the blockbuster block·bust·er n. 1. Something, such as a film or book, that sustains widespread popularity and achieves enormous sales. 2. A high-explosive bomb used for demolition purposes. 3. model of drug development is alive and well. Since 1986, the number of blockbuster drugs A blockbuster drug is a drug generating more than $1 billion of revenue for its owner each year. The search for blockbusters has been the foundation of the R&D strategy adopted by big pharmaceutical companies, but this looks set to change. has grown continuously, and this growth shows no signs of a slowdown. Specialist-oriented products now account for a growing share of blockbuster drugs. How will this changing product mix impact blockbuster sales? What factors must companies consider to ensure accurate forecasting for these higher-priced products? The full exploitation of blockbuster potential, both within therapeutic areas and across disease indications, has been important to industry growth. Will this trend continue even as the number of new products continues to languish? Which therapeutic areas offer the greatest potential for indication proliferation proliferation /pro·lif·er·a·tion/ (pro-lif?er-a´shun) the reproduction or multiplication of similar forms, especially of cells.prolif´erativeprolif´erous pro·lif·er·a·tion n. ? Fears that pharmacogenomics Pharmacogenomics is the branch of pharmacology which deals with the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity. spells the imminent demise of blockbusters are unfounded. Which recent blockbusters have proved this premise to be wrong? How can pharma companies broaden their forecasting vision for these new pharmacogenomic drugs? Under-forecasting of blockbuster products threatens to limit the commercial potential of the industry, and higher standards of forecasting are needed. What industry factors are causing this tendency to under-forecast? How can companies combat under-forecasting in order to identify the true potential of their blockbuster products? Scope of the report: -- Pharmaceutical industry growth in the blockbuster era: an examination of how the industry has managed to sustain healthy growth despite the drop in new product launches. -- Blockbusters, 2005 and 1995: an analysis of blockbusters past and present and how the mix of products has changed. -- Why blockbuster numbers continue to rise: a discussion of indication proliferation and under-forecasting of blockbuster potential. -- Impact of pharmacogenomics: a recent chronology chronology, n the arrangement of events in a time sequence, usually from the beginning to the end of an event. of events and a discussion of the arrival and impact of pharmacogenomic blockbusters. -- Outlook: a discussion of the dangers of under-forecasting and the need to improve forecasting going forward in order to more readily identify potential blockbusters. Companies mentioned: Abbott Altana Amgen Astellas AstraZeneca Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec Biovail Boehringer Ingelheim Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Chugai Daiichi Sankyo Dainippon Sumitomo Eisai Forest Laboratories Genentech GlaxoSmithKline Johnson & Johnson King Eli Lilly Eli Lilly can refer to:
Lundbeck MedImmune Merck Novartis Otsuka Pfi zer Procter & Gamble Roche Sanofi -Aventis Schering Schering-Plough Serono Takeda Tanabe TAP Teva UCB UCB - University of California at Berkeley Wyeth For more information visit http://www.researchandmarkets.com/reports/c46412 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion